XENCOR INC (XNCR) Stock Price, Quote, News and Overview
NASDAQ:XNCR - Nasdaq - US98401F1057 - Common Stock - Currency: USD
XNCR Quote, Performance and Key Statistics
NASDAQ:XNCR (8/4/2025, 3:50:03 PM)
7.975
-0.01 (-0.06%)
The current stock price of XNCR is 7.975 USD. In the past month the price decreased by -5.23%. In the past year, price decreased by -58.39%.
XNCR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.56 | 347.12B | ||
| AMGN | AMGEN INC | 14.54 | 162.32B | ||
| GILD | GILEAD SCIENCES INC | 14.78 | 142.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 121.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.5 | 61.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 54.62B | ||
| ARGX | ARGENX SE - ADR | 74.15 | 42.07B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.81 | 32.90B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.37B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 21.75B | ||
| INSM | INSMED INC | N/A | 20.92B | ||
| BIIB | BIOGEN INC | 8.23 | 19.32B |
Related stock screener links
About XNCR
Company Profile
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. The company is headquartered in Pasadena, California and currently employs 250 full-time employees. The company went IPO on 2013-12-03. The company has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Company Info
XENCOR INC
465 N. Halstead St., Suite 200
Pasadena CALIFORNIA 91016 US
CEO: Bassil I. Dahiyat
Employees: 250
Phone: 16263055900
XENCOR INC / XNCR FAQ
What is the stock price of XENCOR INC today?
The current stock price of XNCR is 7.975 USD. The price decreased by -0.06% in the last trading session.
What is the ticker symbol for XENCOR INC stock?
The exchange symbol of XENCOR INC is XNCR and it is listed on the Nasdaq exchange.
On which exchange is XNCR stock listed?
XNCR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for XENCOR INC stock?
18 analysts have analysed XNCR and the average price target is 29.69 USD. This implies a price increase of 272.33% is expected in the next year compared to the current price of 7.975. Check the XENCOR INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is XENCOR INC worth?
XENCOR INC (XNCR) has a market capitalization of 567.58M USD. This makes XNCR a Small Cap stock.
How many employees does XENCOR INC have?
XENCOR INC (XNCR) currently has 250 employees.
What are the support and resistance levels for XENCOR INC (XNCR) stock?
XENCOR INC (XNCR) has a support level at 7.67 and a resistance level at 8.8. Check the full technical report for a detailed analysis of XNCR support and resistance levels.
Is XENCOR INC (XNCR) expected to grow?
The Revenue of XENCOR INC (XNCR) is expected to grow by 76.03% in the next year. Check the estimates tab for more information on the XNCR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy XENCOR INC (XNCR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of XNCR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of XNCR, evaluating the profitability, health, valuation and growth aspects
- XENCOR INC (XNCR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- XENCOR INC (XNCR) Sales and EPS estimates to see what analysts future expectations are.
- XENCOR INC (XNCR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- XENCOR INC (XNCR) Insider and Institutional Ownership to learn about the owners and their transactions.
- XENCOR INC (XNCR) Stock Chart to make your own analysis
- XENCOR INC (XNCR) Latest news and press-releases to stay up to date.
Does XENCOR INC (XNCR) stock pay dividends?
XNCR does not pay a dividend.
When does XENCOR INC (XNCR) report earnings?
XENCOR INC (XNCR) will report earnings on 2025-11-04, after the market close.
What is the Price/Earnings (PE) ratio of XENCOR INC (XNCR)?
XENCOR INC (XNCR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.06).
What is the Short Interest ratio of XENCOR INC (XNCR) stock?
The outstanding short interest for XENCOR INC (XNCR) is 12.51% of its float. Check the ownership tab for more information on the XNCR short interest.
XNCR Technical Analysis
XNCR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to XNCR. XNCR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
XNCR Financial Highlights
Over the last trailing twelve months XNCR reported a non-GAAP Earnings per Share(EPS) of -3.06. The EPS decreased by -39.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.54% | ||
| ROE | -33.29% | ||
| Debt/Equity | 0.16 |
XNCR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to XNCR. The Buy consensus is the average rating of analysts ratings from 18 analysts.
For the next year, analysts expect an EPS growth of 11.71% and a revenue growth 76.03% for XNCR